Tenon Medical raises $3M in warrant private placement

Q: How much capital did Tenon Medical (TNON) raise in the private placement?

Tenon Medical raised gross proceeds of $2,999,404.59 from the private placement, with up to an additional $597.61 possible upon full exercise of the pre-funded warrants, before deducting a 7% placement agent fee and other offering expenses.

Q: What are the key terms of Tenon Medical (TNON) Series A warrants?

The Series A warrants permit the purchase of up to 1,058,517 common shares at an exercise price of $5.02 per share, are immediately exercisable, expire five years from issuance, and include a beneficial ownership cap of 4.99% that can be increased up to 9.99% with 61 days’ notice.

Q: What are the terms of Tenon Medical (TNON) pre-funded warrants?

The pre-funded warrants cover up to 597,610 shares, were sold at $5.019 per pre-funded warrant, and are exercisable at a nominal price of $0.001 per share until fully exercised, subject to a 9.99% beneficial ownership limitation for the holder.

Tenon Medical, Inc. (TNON) entered into a securities purchase agreement with an institutional investor for a private placement of pre-funded and Series A warrants, which closed on August 31, 2026.

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Tenon Medical, Inc. (TNON) entered into a securities purchase agreement with an institutional investor for a private placement of pre-funded and Series A warrants, which closed on August 31, 2026. The deal covers pre-funded warrants to purchase up to 597,610 shares of common stock at $5.019 per pre-funded warrant and Series A warrants to purchase up to 1,058,517 shares at an exercise price of $5.02 per share, generating gross proceeds of $2,999,404.59 (plus up to $597.61 upon pre-funded warrant exercise).

The Series A warrants are immediately exercisable for five years, subject to a 4.99%–9.99% beneficial ownership cap, while the pre-funded warrants are exercisable at $0.001 per share with a 9.99% cap. Tenon agreed to pay WallachBeth Capital a 7% cash fee on gross proceeds and to file a resale registration statement for the underlying shares within 15 days, targeting effectiveness within 45 days (or 75 days after a full SEC review). Tenon plans to use net proceeds for repayment of certain debt, working capital and general corporate purposes.

Filing Explained

The placement is closed, but its warrants preserve potential additional share issuance that could reduce existing holders’ ownership percentages if exercised.

The August 31 closing completed the private placement, but the filing records warrants and not an already completed issuance of all shares underlying them.

If exercised, the pre-funded and Series A warrants could result in additional common shares; under the supplied dilution definition, that would reduce existing holders’ percentage ownership absent offsetting changes.

The resale registration commitment addresses future resale of the underlying shares; it does not itself establish that the warrants have been exercised or that those shares have been sold.

As of June 30, 2026, Tenon had $1.677 million of cash and equivalents, which equals 55.3 days of the last reported quarterly operating cash use.

Sources and calculations

Tenon Medical Form 8-K (2026-08-31)
Dilution definition (undated)
Pre-funded warrant definition (undated)
Tenon Medical latest quarterly fundamentals (2026-06-30)

Available liquidity against the last reported quarterly operating outflow, in days at that rate $1,677,000 / ($2,758,000 / 91) = 55.3 days

8-K Event Classification

4 items: 1.01, 3.02, 8.01, 9.01

4 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 3.02 Unregistered Sales of Equity Securities Securities

The company sold equity securities in a private placement or other unregistered transaction.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Pre-Funded Warrants Shares: 597,610 shares Series A Warrant Shares: 1,058,517 shares Pre-Funded Warrant Purchase Price: $5.019 per pre-funded warrant +5 more

8 metrics

Pre-Funded Warrants Shares 597,610 shares Maximum number of shares issuable upon exercise of pre-funded warrants

Series A Warrant Shares 1,058,517 shares Maximum number of shares issuable upon exercise of Series A warrants

Pre-Funded Warrant Purchase Price $5.019 per pre-funded warrant Purchase price in the private placement

Series A Warrant Exercise Price $5.02 per share Exercise price of Series A warrants

Gross Proceeds $2,999,404.59 Gross proceeds received from the private placement

Placement Agent Fee 7% of gross proceeds Cash fee payable to WallachBeth Capital LLC

Beneficial Ownership Cap (Series A Warrants) 4.99%–9.99% Maximum post-exercise ownership allowed for holder

Registration Filing Deadline 15 days Deadline after Registration Rights Agreement to file resale registration statement

Key Terms

Pre-Funded Warrants, Series A Warrants, Registration Rights Agreement, Section 4(a)(2), +1 more

5 terms

Pre-Funded Warrants financial

"issuance and sale in a private placement of (i) pre-funded warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

Series A Warrants financial

"and (ii) Series A warrants to purchase up to an aggregate"

Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.

Registration Rights Agreement regulatory

"entered into a registration rights agreement (the “Registration Rights Agreement”)"

A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.

Section 4(a)(2) regulatory

"reliance on the exemptions from registration provided by Section 4(a)(2)"

Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.

Regulation D regulatory

"and Regulation D promulgated thereunder"

Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.

FAQ

What financing transaction did Tenon Medical (TNON) announce in this 8-K?

Tenon Medical entered into a private placement with an institutional investor involving pre-funded warrants for up to 597,610 shares and Series A warrants for up to 1,058,517 shares of common stock, generating gross proceeds of $2,999,404.59 before fees and expenses.

How much capital did Tenon Medical (TNON) raise in the private placement?

Tenon Medical raised gross proceeds of $2,999,404.59 from the private placement, with up to an additional $597.61 possible upon full exercise of the pre-funded warrants, before deducting a 7% placement agent fee and other offering expenses.

What are the key terms of Tenon Medical (TNON) Series A warrants?

The Series A warrants permit the purchase of up to 1,058,517 common shares at an exercise price of $5.02 per share, are immediately exercisable, expire five years from issuance, and include a beneficial ownership cap of 4.99% that can be increased up to 9.99% with 61 days’ notice.

What are the terms of Tenon Medical (TNON) pre-funded warrants?

The pre-funded warrants cover up to 597,610 shares, were sold at $5.019 per pre-funded warrant, and are exercisable at a nominal price of $0.001 per share until fully exercised, subject to a 9.99% beneficial ownership limitation for the holder.

How will Tenon Medical (TNON) use the proceeds from the private placement?

Tenon Medical states it intends to use the net proceeds from the private placement for repayment of certain debt, as well as for working capital and general corporate purposes.

What registration rights did Tenon Medical (TNON) grant to the investor?

Tenon Medical agreed to file a registration statement for resale of the pre-funded warrant shares and Series A warrant shares within 15 days of the Registration Rights Agreement and to use best efforts to have it declared effective within 45 days, or 75 days if subject to full SEC review.

Under what exemptions were Tenon Medical (TNON) securities issued?

The pre-funded warrants, Series A warrants, and underlying common shares were issued, or will be issuable, in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and Regulation D, and were not registered under federal or state securities laws.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/31/2026 - 03:41 PM Accepted by SEC EDGAR 08/31/2026 - 03:40 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):

August 27, 2026

TENON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-41364	45-5574718
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of incorporation)		Identification No.)

104 Cooper Court
Los Gatos, CA		95032
(Address of principal executive offices)		(Zip Code)

(408) 649-5760

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	TNON	The Nasdaq Stock Market LLC
Warrants	TNONW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On August 27, 2026, Tenon Medical, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”) for the issuance and sale in a private placement (the “Private Placement”) of (i) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 597,610 shares (the “Pre-Funded Warrant Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $5.019 per Pre-Funded Warrant, and (ii) Series A warrants to purchase up to an aggregate of 1,058,517 shares of Common Stock (the “Series A Warrants,” and the shares issuable upon exercise thereof, the “Series A Warrant Shares”). The Private Placement closed on August 31, 2026. The Company received gross proceeds of $2,999,404.59 (which does not include $597.61 that the Company may receive from the Purchaser upon exercise of the Pre-Funded Warrants) from the Private Placement.

Each Series A Warrant has an exercise price of $5.02 per share. The Series A Warrants are immediately exercisable and will expire five (5) years from issuance. A holder may not exercise any portion of the Series A Warrants to the extent the Purchaser would own more than 4.99% of the outstanding Common Stock immediately after exercise. A holder may increase or decrease this percentage with respect to the Series A Warrants to a percentage not in excess of 9.99%, except that any such increase shall require at least 61 days’ prior notice to the Company.

The Pre-Funded Warrants are immediately exercisable and may be exercised at a nominal exercise price of $0.001 per share of Common Stock at any time until all of the Pre-Funded Warrants are exercised in full. A holder may not exercise any portion of the Pre-Funded Warrants to the extent the Purchaser would own more than 9.99% of the outstanding Common Stock immediately after exercise.

WallachBeth Capital LLC (the “Placement Agent”) served as the Company’s exclusive placement agent in connection with the Private Placement, pursuant to that certain placement agency agreement, dated as of August 27, 2026, between the Company and Placement Agent (the “Placement Agency Agreement”). Pursuant to the Placement Agency Agreement, the Company agreed to pay the Placement Agent a cash fee of 7% of the aggregate gross proceeds raised in the Private Placement and agreed to reimburse the Placement Agent for certain expenses and legal fees.

The Placement Agency Agreement and the Purchase Agreement contain customary representations and warranties, agreements and obligations, conditions to closing and termination provisions.

In connection with the Private Placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”), dated as of August 31, 2026, with the Purchaser, pursuant to which the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of the Pre-Funded Warrant Shares and the Series A Warrant Shares no later than 15 days after the date of the Registration Rights Agreement, and to use best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 45 days following the date of the Registration Rights Agreement (or 75 days following the date of the Registration Rights Agreement in the event of a “full review” by the SEC).

The Private Placement closed on August 31, 2026. The Company intends to use the net proceeds received from the Private Placement for repayment of certain debt, working capital and general corporate purposes.

The foregoing descriptions of terms and conditions of the Placement Agency Agreement, the Purchase Agreement, the Pre-Funded Warrants, the Series A Warrants, and the Registration Rights Agreement do not purport to be complete and are qualified in their entirety by the full text of the form of the Placement Agency Agreement, the Purchase Agreement, the form of the Pre-Funded Warrant, the form of the Series A Warrant, and the form of the Registration Rights Agreement, which are attached hereto as Exhibits 1.1, 10.1, 4.1, 4.2, and 10.2, respectively.

Item 3.02 Unregistered Sales of Equity Securities.

The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Neither the issuance of the Pre-Funded Warrants, the Series A Warrants, or the shares of Common Stock issuable upon exercise thereof, as applicable, were registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws. The issuance of the Pre-Funded Warrants and the Series A Warrants were and the shares of Common Stock issuable upon the exercise thereof will be issued in reliance on the exemptions from registration provided by Section 4(a)(2) under the Securities Act and Regulation D promulgated thereunder.

Item 8.01 Other Events.

On August 28, 2026, the Company issued a press release announcing the pricing of the Private Placement. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

On August 31, 2026, the Company issued a press release announcing the closing of the Private Placement. A copy of this press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

The information set forth in this Item 8.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished with this Current Report on Form 8-K:

Exhibit		Description
1.1		Placement Agency Agreement dated August 27, 2026
4.1		Form of Pre-Funded Warrant
4.2		Form of Series A Warrant
10.1*		Form of Securities Purchase Agreement
10.2*		Form of Registration Rights Agreement
99.1		Press Release issued by Tenon Medical, Inc. dated August 28, 2026
99.2		Press Release issued by Tenon Medical, Inc., dated August 31, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Schedules and similar attachments have been omitted pursuant to Regulation S-K Item 601(a)(5). The Company agrees to furnish a supplemental copy of any omitted schedule or attachment to the SEC upon request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 31, 2026	TENON MEDICAL, INC.
	(Registrant)

	By:	/s/ Steven M. Foster
	Name:	Steven M. Foster
	Title:	Chief Executive Officer and President

Exhibit 99.1

Tenon Medical Announces Pricing of $3M Private Placement Offering

LOS GATOS, CA – August 28, 2026 – Tenon Medical, Inc. (Nasdaq: TNON), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced that on August 27, 2026 it has entered into a securities purchase agreement with an institutional investor to sell 597,610 shares of common stock (or pre-funded warrants in lieu thereof), together with a warrant to purchase up to an aggregate 1,058,517 shares of common stock, in a private placement offering. The combined effective offering price for each share of common stock and accompanying warrants to be issued is $5.02. The combined effective offering price for each pre-funded warrant and accompanying warrants to be issued is $5.019. The pre-funded warrants will have an exercise price of $0.001 per share of common stock and the warrant will have an exercise price of $5.02 per share, will be immediately exercisable, and will expire five years from the date of issuance.

The gross proceeds to the Company from the offering are estimated to be approximately $3.0 million before deducting the placement agent’s fees and other estimated offering expenses. The offering is expected to close on or about August 31, 2026, subject to the satisfaction of customary closing conditions.

WallachBeth Capital LLC is acting as the exclusive placement agent in connection with the offering.

The offer and sale of the foregoing securities are being made in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, and the securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to the terms of the securities purchase agreement, the Company has agreed to provide customary registration rights for the shares of common stock and the shares of common stock underlying the warrants and pre-funded warrants.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

About Tenon Medical, Inc.

Tenon Medical, Inc. is a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. Tenon was incorporated in the State of Delaware in 2012 and currently offers two systems to treat a diseased sacroiliac joint (the “SI Joint”). The Company has developed The Catamaran™ SI Joint Fusion System that offers a novel, less invasive approach to the SI Joint using a single, robust titanium implant. In August 2025, the Company acquired substantially all of the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry+^® SI Joint Fusion System, which treats disorders of the SI Joint through a minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles. Since the national launch of The Catamaran System in October 2022, Tenon is focused on three commercial opportunities: 1) primary SI Joint procedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint fusion adjunct to a spine fusion construct.

For more information, please visit www.tenonmed.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.

The Tenon Medical logo shown above, and Catamaran^{^®}, PiSIF^®, CAT PiSIF^®, ETAD^®, Posterior Inferior Sacroiliac Fusion^®, CAT SIJ Fusion System^®, Catamaran SIJ Fusion System^®, Catamaran Inferior Posterior Fusion System^®, Catamaran Transfixation Fusion System^®, Catamaran Transfixation Fusion Device^®, SImmetry^® are registered trademarks of Tenon Medical, Inc. MAINSAIL™, and SImmetry+ are also trademarks of Tenon Medical, Inc.

Forward-Looking Statements

This press release contains “forward-looking statements,” which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking statements often contain words such as “intends,” “estimates,” “anticipates,” “hopes,” “projects,” “plans,” “expects,” “seek,” “believes,” “see,” “should,” “will,” “would,” “target,” and similar expressions and the negative versions thereof. These forward-looking statements, include, but are not limited to, statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering and the anticipated use of proceeds therefrom. Such statements are based on Tenon’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause Tenon’s actual results to be materially different than those expressed in any forward-looking statements, please review Tenon’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and updated from time to time in our Form 10-Q filings and in our other public filings on file with the SEC at www.sec.gov, particularly the information contained in the section entitled “Risk Factors.” We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.

Investor Contact

Shannon Devine
MZ North America
203-741-8811
tenon@mzgroup.us

Exhibit 99.2

Tenon Medical Announces Closing of $3M Private Placement Offering

LOS GATOS, CA – August 31, 2026 – Tenon Medical, Inc. (Nasdaq: TNON), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, has closed its previously announced private placement pursuant to securities purchase agreement with an institutional investor to sell 597,610 shares of common stock (or pre-funded warrants in lieu thereof), together with a warrant to purchase up to an aggregate 1,058,517 shares of common stock, in a private placement offering. The combined effective offering price for each share of common stock and accompanying warrants to be issued is $5.02. The combined effective offering price for each pre-funded warrant and accompanying warrants to be issued is $5.019. The pre-funded warrants will have an exercise price of $0.001 per share of common stock and the warrant will have an exercise price of $5.02 per share, will be immediately exercisable, and will expire five years from the date of issuance.

The gross proceeds to the Company from the offering are estimated to be approximately $3.0 million before deducting the placement agent’s fees and other estimated offering expenses.

WallachBeth Capital LLC acted as the exclusive placement agent in connection with the offering.

About Tenon Medical, Inc.

Tenon Medical, Inc. is a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. Tenon was incorporated in the State of Delaware in 2012 and currently offers two systems to treat a diseased sacroiliac joint (the “SI Joint”). The Company has developed The Catamaran™ SI Joint Fusion System that offers a novel, less invasive approach to the SI Joint using a single, robust titanium implant. In August 2025, the Company acquired substantially all of the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry+® SI Joint Fusion System, which treats disorders of the SI Joint through a minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles. Since the national launch of The Catamaran System in October 2022, Tenon is focused on three commercial opportunities: 1) primary SI Joint procedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint fusion adjunct to a spine fusion construct.

For more information, please visit www.tenonmed.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.

The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAIL™, and SImmetry+ are also trademarks of Tenon Medical, Inc.

Forward-Looking Statements

Investor Contact

Shannon Devine
MZ North America
203-741-8811
tenon@mzgroup.us

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

11 documents